Hypertension is a major risk factor for CVD
Clinical trials establishing tirzepatide's efficacy (SURMOUNT-1, SURMOUNT-2, SURMOUNT-3) tested the same tirzepatide molecule now available through compounding
If you have contacted your PBM and they do not have your prior authorization on file, even though you received communication from us confirming its submission, please give us a call at 1-888-729-0438
The SELECT study is an ongoing trial with the objective of determining the superiority of semaglutide to placebo with respect to the prevention of major adverse cardiovascular events in patients with overweight or obesity who have established cardiovascular disease, but do not have diabetes
Unlike classical growth factors, BPC-157 exhibits a high degree of stability in gastric juice and oral bioavailability in animal studies, suggesting potential for systemic therapeutic effects
This article delves into the emerging benefits and potential risks associated with these powerful drugs, offering a comprehensive overview for patients and healthcare providers
